

2018 YEAR-IN-REVIEW

Plan Sustainability

38.9%

of clients experienced flat-lined or decreasing PMPM¹ drug spend over past 3 years

Excluding SA² drugs,

77.8%

of clients experienced flat-lined or decreasing PMPM drug spend over past 3 years



2.9%

Inflation rate, excluding SA drugs, among Reformulary subscribed clients



Generic penetration rate³

Insights



Number of pipeline⁴ drugs being monitored by us in 2018

174



13.6 Million Lives

Size of our database used to mine insights and apply predictive tools

National coverage for peer-reviewed report,

“Opioid prescribing: Is it contributing to the opioid crisis?”

[LEARN MORE ▶](#)

Innovations

drugfinder



792,292

Drug searches in DrugFinder[®] - putting the power in the hands of the patient



Winner

TELUS Outstanding Product Award, for DrugFinder[®]

Cannabis standard



**10 Months
Thousands of Hours**

Invested in reviewing clinical evidence globally and building medical cannabis formulary



Quality of Life

Initial focus of our research platform, measuring benefit of medical cannabis on quality of life

¹ Per Member Per Month

² Special Authorization (SA) drugs include drugs requiring prior approval, including specialty drugs

³ Generic penetration rate defined as rate at which generic drug is substituted for original brand drug

⁴ Drugs currently in the Health Canada regulatory review process, prior to receiving a Notice of Compliance (NOC)

Experts with benefits: we want to make a Remarkable difference.
Contact us today to learn more Helen.Stevenson@reformulary.com

reformulary[®]
GROUP



416-519-9729 | reformulary.com | drugfinder.ca | cannabisstandard.com